U.S. Appeals Court Panel Rejects Bid To Halt CDC Eviction Moratorium

-Reuters

-Reuters

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Enhertu Significantly Improved Progression-free Survival in DESTINY-breast03 Head-to-head Trial Vs. Trastuzumab Emtansine (T-dm1) in Patients With HER2-positive Metastatic Breast Cancer

Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca (NYSE: AZN) and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superiority over trastuzumab emtansine (T-DM1).

AZN